Tvardi Therapeutics, Inc. (TVRD NASDAQ) stock market data APIs
$27.4754
-3.94(-14.3%)
as of July 11, 2025
Try our APIs with
free plan!
Tvardi Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.
Prev. Close
27.4754
Open
23.5327
High
27.6869
Low
23.0659
52 wk Range
8.136-34.31
Market Cap
0
EPS
-0.5
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tvardi Therapeutics, Inc. data using free add-ons & libraries
Get Tvardi Therapeutics, Inc. Fundamental Data
Tvardi Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tvardi Therapeutics, Inc. News
New
Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating
Investing.com - Cantor Fitzgerald initiated coverage on Tvardi Therapeutics Inc (NASDAQ:TVRD) with an Overweight rating and a price target of $52.00 on Friday. The $212 million market cap company curr...
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff stance reignited demand for risk assets, triggering the market’s biggest monthly rally si...
Tvardi Therapeutics files to sell 2.08M shares of common stock for holders
* Tvardi Therapeutics (NASDAQ:TVRD [https://seekingalpha.com/symbol/TVRD]) files to sell 2.08M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10046911] MORE ON TVAR...
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi shares to beg...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
